Shares of Alcobra Ltd. (NASDAQ:ADHD) gapped up prior to trading on Friday . The stock had previously closed at $1.30, but opened at $1.51. Alcobra shares last traded at $1.57, with a volume of 4,450,475 shares.

Several brokerages have commented on ADHD. Zacks Investment Research cut shares of Alcobra from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Roth Capital cut shares of Alcobra from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $4.00 to $1.00 in a research note on Friday, September 29th. Finally, WBB Securities upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Monday, October 9th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $1.56.

The stock’s 50 day moving average is $1.10 and its 200 day moving average is $1.12. The firm’s market cap is $43.82 million.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. On average, equities analysts anticipate that Alcobra Ltd. will post ($0.77) earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC boosted its position in Alcobra by 7,251.0% during the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 101,514 shares during the last quarter. Worth Venture Partners LLC boosted its position in Alcobra by 35.6% during the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after acquiring an additional 71,465 shares during the last quarter. Finally, Royce & Associates LP boosted its position in Alcobra by 15.5% during the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after acquiring an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 29.68% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alcobra Ltd. (ADHD) Shares Gap Up to $1.51” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://theolympiareport.com/2017/10/20/alcobra-ltd-adhd-shares-gap-up-to-1-51.html.

Alcobra Company Profile

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.